Summary

In PALACE-1 trial apremilast, an oral phosphodiesterase 4 inhibitor, was shown to be safe and effective in treating psoriatic arthritis (PsA) in subjects previously exposed to disease-modifying antirheumatic drugs. Apremilast modulates the production of pro- (tumor necrosis factor-a, natural killer cells, and epidermal keratinocytes) and anti-inflammatory mediators (interleukin-10), including those implicated in the etiopathogenesis of PsA.